Atrys Health (XMAD:ATRY) Tariff Resilience Score: 0/10 (As of Jun. 29, 2026)


XMAD:ATRY Atrys Health SA XMAD:ATRY
68 GF Score
Price €2.55
GF Value €3.11
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Atrys Health Tariff Resilience Score?

Atrys Health has the Tariff Resilience Score of 0, which implies that the company might have .

Atrys Health has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Atrys Health might have .

Atrys Health  (XMAD:ATRY) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Atrys Health Tariff Resilience Score Related Terms

XMAD:ATRY
68GF Score
Atrys Health SA XMAD:ATRY
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.55 is trading 18% below its estimated GF Value™ of €3.11. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

  • Tariff Resilience Score: 0
  • GF Value™: €3.11 vs. price of €2.55 (18% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atrys Health Business Description

Other Exchanges A2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
68GF Score

Get the complete analysis for XMAD:ATRY

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.55
Price
€3.11
GF Value